Is sarcopenia a missed factor in the management of patients with metastatic breast cancer?

Background: Sarcopenia has emerged as an important parameter to predict outcomes and treatment toxicity. However, limited data are available to assess sarcopenia prevalence in metastatic breast cancer and to evaluate its management.

Methods: The SCAN study was a cross-sectional multicenter French study that aimed to estimate sarcopenia prevalence in a real-life sample of metastatic cancer patients.

[Anemia in the elderly: diagnosis and therapeutic approach].

Anaemia is particularly common amongthe elderly population. It is necessary, with the aid of the mean glomerular volume, to determine if it is microcytic, normocytic or macrocytic. Similarly, the level of reticulocytes indicates whether the anaemia is regenerative or non-regenerative.